Dr. Asit Kr Paul, MD, PhD

Dr. Paul practices at VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia.

Dr. Paul's NPI, 1124277645, was assigned on September 9, 2008. Dr. Paul holds Virginia license 0101253731.

Dr. Paul's primary practice is VCU Medical Center, at 1250 East Marshall Street, Richmond, VA 23298 in Richmond City. The practice phone is (804) 828-9000.

Dr. Paul's primary practice is VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia. Dr. Paul is also affiliated with VCU Health Tappahannock Hospital. The medical group on file is MCV Physicians. Dmand AI also links Dr. Paul to 1 more hospital and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Paul practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Paul's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Paul is board certified in hematology by the American Board of Internal Medicine. Dr. Paul is licensed in Virginia.

CMS data shows 861 Medicare services from Dr. Paul across 8 procedure codes in 2024, for 260 Medicare patients. Medicare paid $59,676 for them.

CMS counts 260 Medicare patients who saw Dr. Paul in 2024. The largest group is 65 to 74, with 132 patients. 75% of them have cancer, and 75% have high blood pressure. 8% are also on Medicaid. Their average risk score is 2.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Paul's median patient age at 73, with 21% women.

In 2024, Dr. Paul wrote 661 Medicare Part D claims for 120 patients. 66% of them were for generic drugs. CMS names the drug for 531 of them, across 13 drugs with 11 or more claims each, at $2,490,197 in total drug cost. In 2023, CMS named 433 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Paul for performance year 2024, reported as part of a group. Dr. Paul accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Paul as offering telehealth.

Dmand AI links 26 papers to Dr. Paul, published from 2011 to 2025. 2022 was the busiest year, with 5. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Prostatic Neoplasms. Dr. Paul has published most often in Cureus. Dr. Paul's most frequent co-authors are Samina Hirani, MBBS, John W. Melson, MD and Bohdan Baralo, MD.

Dmand AI links Dr. Paul to 9 clinical trials, 5 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 18 general payments to Dr. Paul from 7 drug and device companies from 2018 to 2024. Consulting fees make up the largest share, 72% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $2,808.